Preeclampsia is a condition in which blood pressure and proteinuria increase in pregnant women. If left untreated, it can cause many dangerous complications. The disease can be screened through a number of preeclampsia tests.

SFlt-1 is a protein that acts as an antagonist to PlGF (which promotes angiogenesis). Therefore, sFlt-1 reduces angiogenesis and is known as an anti-angiogenic factor. Quantitative testing of sFlt-1 (in combination with PlGF) is often indicated in the early diagnosis and differential diagnosis of preeclampsia.

Preeclampsia is one of the obstetric complications that cause serious consequences for the mother and fetus. In order to minimize the negative effects of preeclampsia, scientists have found that changes in the concentration of pluripotent factor (PlGF) and anti-angiogenic factor (sFlt-1) occur quite early before the symptoms of preeclampsia appear. Therefore, it is possible to quantify pluripotent factor for early diagnosis of preeclampsia.

Preeclampsia is a disease in pregnant women during pregnancy. The disease can leave many serious complications and serious consequences if not detected and treated promptly and properly. One of the methods to detect preeclampsia early and effectively screen for the disease is the sFlt1 quantitative test.